Annotation Detail
Information
- Associated Genes
- RRM1
- Associated Variants
-
RRM1 UNDEREXPRESSION
(
ENST00000300738.10 )
RRM1 UNDEREXPRESSION ( ENST00000300738.10 ) - Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- In this study, 229 tumors were analyzed for RRM1 expression. This resulted in 146 that were negative for RRM1 expression and 83 that were positive. These tumors were studied for a relationship between RRM1 expression and chemotherapy regimens, gemcitabine, docetaxel and carboplatin, and vinorelbine and carboplatin. In the patients receiving gemcitabine treatment, the progression-free survival of RRM1-negative patients was significantly higher than that of RRM1-positive patients (8.8 months vs. 7.6 months, P = 0.01). The patients that were positive for RRM1 expression, had a better response to docetaxel or vinorelbine treatment than gemcitabine (P=0.047 and P=0.047). However, there were no differences of response to docetaxel and vinorelbine in regards to RRM1 expression.
- Variant Origin
- N/A
- Variant Origin
- N/A
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/5530
- Gene URL
- https://civic.genome.wustl.edu/links/genes/5051
- Variant URL
- https://civic.genome.wustl.edu/links/variants/1257
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Docetaxel,Gemcitabine,Vinorelbine
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 24647522
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Docetaxel | Sensitivity | true |
| Gemcitabine | Sensitivity | true |
| Vinorelbine | Sensitivity | true |